Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 11/20 | 0.54 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethionine SCHEMBL840665 | 1.00 | BHMT (0.54) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL7073863 | 0.91 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL8967 | 0.91 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL8966 | 0.91 | BHMT (0.63) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL28989455 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL11572299 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL28999714 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL31567824 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL3348592 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 | |
| Ethionine SCHEMBL11571773 | 0.89 | BHMT (0.61) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | SANOFI (FR) | 2024-02-08 | — | — | US | disclosed |
| EP-4214308-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | Sanofi (FR) | 2023-07-26 | — | — | EP | disclosed |
| WO-2023069727-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPROLIFERATIVE, INFLAMMATORY, AND IMMUNOLOGICAL DISEASES, AND INFECTIONS | EDISON ONCOLOGY (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2017029498-A1 | 2-SULFONYLPYRIMIDINES | MEDICAL RESEARCH COUNCIL (GB) | 2017-02-23 | — | — | WO | disclosed |
| US-20130331457-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8377985-B2 | Treatment of cancer | BIPAR SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120238601-A1 | TREATMENT OF CANCER | BIPAR SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012095514-A1 | RECOMBINANT PROTEIN PRODUCTION SYSTEM | VIVALIS (FR) | 2012-07-19 | — | — | WO | disclosed |
| US-8143447-B2 | Benzamide precursor with sulfur substituent; poly-ADP-ribose polymerase inhibitors, antitumor agents; leukemia, breast, ovarian, lung, bladder, prostate, pancreatic, and cervical cancers | BIPAR SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-7888417-B2 | core or the layer includes a composition formed from a base polymer, a crosslink initiator, and at least one additive; additive has at least one carbon-oxygen-boron linkage, carbon in the linkage being a secondary or tertiary carbon; enhances coefficient of restitution and/or reduces compression of core | ACUSHNET COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-20060281586-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-12-14 | — | — | US | disclosed |
| US-20060281587-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2006-12-14 | — | — | US | disclosed |
| US-20050277132-A1 | Nematode GS-like sequences | DIVERGENCE INC., A DELAWARE CORPORATION | 2005-12-15 | — | — | US | disclosed |
| WO-2005115372-A1 | DECREASING BRAIN NEURONAL GLUTAMATE LEVELS USING ALPHA-KETO BRANCHED CHAIN AMINO ACIDS | ODESSA PHARMA, LLC (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050245657-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| US-20050245652-A1 | Compositions for use in golf balls | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-11-03 | — | — | US | disclosed |
| WO-2004106489-A2 | Nematode GS-like sequences | DIVERGENCE, INC (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20030235898-A1 | Nematode GS-like sequences | DIVERGENCE, INC. | 2003-12-25 | — | — | US | disclosed |
| EP-0460178-A1 | CD4 SPECIFIC RECOMBINANT ANTIBODY. | ORTHO PHARMA CORP (US) | 1991-12-11 | — | — | EP | disclosed |
| WO-1991009966-A1 | CD4 SPECIFIC RECOMBINANT ANTIBODY | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240043878-A1 | GENERATION OF A HIGH PRODUCING RECOMBINANT CHINESE HAMSTER OVARY CELL LINE FOR THERAPEUTIC PROTEIN PRODUCTION | DHODH, GLUL, GLS2 | BHMT 679/4885BHMT2 1088/4885NOS2 1345/4885 |
| US-20120238601-A1 | TREATMENT OF CANCER | PARP1, PARP2, PARP3 | BHMT 668/4885BHMT2 1044/4885NOS2 2969/4885 |
| US-20130331457-A1 | TREATMENT OF CANCER | IDH3B, NDUFB5, NDUFB7 | BHMT 848/4885BHMT2 293/4885NOS2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.